Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.


Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
11 2019
Historique:
received: 03 01 2019
accepted: 17 04 2019
pubmed: 9 5 2019
medline: 2 6 2020
entrez: 9 5 2019
Statut: ppublish

Résumé

Carbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI). In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-analysis of two genomewide association studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls. HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10

Identifiants

pubmed: 31066027
doi: 10.1002/cpt.1493
pmc: PMC7156285
mid: NIHMS1575961
doi:

Substances chimiques

HLA-A Antigens 0
HLA-B Antigens 0
Carbamazepine 33CM23913M
ALK protein, human EC 2.7.10.1
Anaplastic Lymphoma Kinase EC 2.7.10.1

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1028-1036

Subventions

Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0606-1062
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT098017
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N005953/1
Pays : United Kingdom
Organisme : Department of Health
ID : 09/144/09
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0800637
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : P50 GM115305
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI139021
Pays : United States
Organisme : NIAID NIH HHS
ID : R34 AI136815
Pays : United States

Informations de copyright

© 2019 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

Gastroenterology. 2017 Apr;152(5):1078-1089
pubmed: 28043905
Hum Mol Genet. 2011 Mar 1;20(5):1034-41
pubmed: 21149285
Clin Pharmacol Ther. 2013 Jul;94(1):142-9
pubmed: 23588310
Lancet. 2002 Mar 2;359(9308):727-32
pubmed: 11888582
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Orphanet J Rare Dis. 2011 Jul 29;6:52
pubmed: 21801394
J Dermatol. 2012 Jul;39(7):594-601
pubmed: 22211527
Pharmacol Rev. 2013 Mar 08;65(2):779-808
pubmed: 23476052
Pharmacogenomics J. 2012 Apr;12(2):96-104
pubmed: 21221126
N Engl J Med. 2011 Mar 24;364(12):1134-43
pubmed: 21428769
Pharmacogenomics J. 2017 Dec;17(6):501-505
pubmed: 27527109
Lancet. 2002 Mar 30;359(9312):1121-2
pubmed: 11943262
Clin Cancer Res. 2016 Mar 15;22(6):1371-7
pubmed: 26546620
J Immunol Res. 2017;2017:3406230
pubmed: 28626773
J Allergy Clin Immunol. 2015 Aug;136(2):236-44
pubmed: 26254050
Pharmacogenomics J. 2014 Jun;14(3):281-8
pubmed: 24322785
Basic Clin Pharmacol Toxicol. 2012 Jul;111(1):58-64
pubmed: 22348435
Lancet. 2007 Mar 24;369(9566):1000-15
pubmed: 17382827
Epilepsy Res. 2011 Nov;97(1-2):190-7
pubmed: 21917426
Clin Pharmacol Ther. 2012 Dec;92(6):757-65
pubmed: 23132554
Aliment Pharmacol Ther. 2007 Jun 15;25(12):1411-21
pubmed: 17539980
Clin Pharmacol Ther. 2018 Apr;103(4):574-581
pubmed: 29392710
J Dermatol Sci. 2014 Feb;73(2):101-9
pubmed: 24268988
J Biol Chem. 2001 Mar 23;276(12):9526-31
pubmed: 11121404
Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8
pubmed: 25414323
PLoS One. 2013 Jun 06;8(6):e64683
pubmed: 23762245
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Chem Res Toxicol. 2014 Feb 17;27(2):175-7
pubmed: 24476427
Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115
pubmed: 28050598
Am J Hum Genet. 2008 Sep;83(3):347-58
pubmed: 18760391
Nat Rev Genet. 2010 Jul;11(7):499-511
pubmed: 20517342
Int J Immunogenet. 2013 Feb;40(1):54-9
pubmed: 23136897
Clin Pharmacol Ther. 2011 Jun;89(6):896-901
pubmed: 21562486
Epilepsia. 2010 May;51(5):926-30
pubmed: 20345939
J Immunol Res. 2014;2014:565320
pubmed: 24901010
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
PLoS One. 2007 Sep 05;2(9):e841
pubmed: 17786212
Pharmacogenomics. 2007 Dec;8(12):1661-91
pubmed: 18085998
Front Pharmacol. 2017 Feb 27;8:90
pubmed: 28289388
Clin Pharmacol Ther. 2019 Jul;106(1):245-253
pubmed: 30661239
Nat Genet. 2010 Aug;42(8):711-4
pubmed: 20639878
Nat Methods. 2013 Jan;10(1):5-6
pubmed: 23269371
Pharmacogenomics J. 2014 Apr;14(2):192-200
pubmed: 23712092
Nat Genet. 2009 Jul;41(7):816-9
pubmed: 19483685
JAMA Neurol. 2018 Jul 1;75(7):842-849
pubmed: 29610831
J Exp Med. 1995 Jun 1;181(6):1945-8
pubmed: 7539032
Nucleic Acids Res. 2014 Jan;42(Database issue):D975-9
pubmed: 24297256
Neurology. 2017 Jun 6;88(23):2183-2191
pubmed: 28476759
Nature. 2004 Apr 1;428(6982):486
pubmed: 15057820

Auteurs

Paola Nicoletti (P)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sema4, a Mount Sinai Venture, Stamford, Connecticut, USA.

Sarah Barrett (S)

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Laurence McEvoy (L)

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Ann K Daly (AK)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Guruprasad Aithal (G)

National Institute for Health Research (NIHR) Nottingham Biomedical Research Unit, Center at the Nottingham University Hospital NHS Trust and University of Nottingham, Nottingham, UK.

M Isabel Lucena (MI)

UGC Digestivo, Clinical Pharmacology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Raul J Andrade (RJ)

UGC Digestivo, Clinical Pharmacology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Mia Wadelius (M)

Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Pär Hallberg (P)

Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Camilla Stephens (C)

UGC Digestivo, Clinical Pharmacology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Einar S Bjornsson (ES)

Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland.

Peter Friedmann (P)

Dermatology Unit, School of Medicine, University of Southampton, Southampton, UK.

Kati Kainu (K)

Clinical Research Unit for Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, Finland.

Tarja Laitinen (T)

Clinical Research Unit for Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, Finland.

Anthony Marson (A)

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Mariam Molokhia (M)

School of Population Sciences and Health Services Research, King's College, London, UK.

Elizabeth Phillips (E)

Departiment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Werner Pichler (W)

ADR-AC GmbH, Bern, Switzerland.

Antonino Romano (A)

Allergy Unit, Complesso Integrato Columbus, Rome, Italy.

Neil Shear (N)

Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Graeme Sills (G)

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Luciana K Tanno (LK)

Hospital Sírio Libanês, São Paulo, Brazil.

Ashley Swale (A)

Department of Systems Biology, Columbia University, New York, New York, USA.

Aris Floratos (A)

Department of Systems Biology, Columbia University, New York, New York, USA.

Yufeng Shen (Y)

Department of Systems Biology, Columbia University, New York, New York, USA.

Matthew R Nelson (MR)

Target Sciences, GSK, King of Prussia, Pennsylvania, USA.

Paul B Watkins (PB)

Eshelman School of Pharmacy, University of North Carolina Institute for Drug Safety Sciences, Chapel Hill, North Carolina, USA.

Mark J Daly (MJ)

Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Andrew P Morris (AP)

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Department of Biostatistics, University of Liverpool, Liverpool, UK.

Ana Alfirevic (A)

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Munir Pirmohamed (M)

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH